Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch

BioSpace

While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given

CommercialMetabolic & GLP-1Read full story